Abstract
Sym004 is a new antibody mixture to target EGFR in metastatic colorectal cancer. Preclinical data suggest efficacy in anti–EGFR-resistant tumors, but it remains unclear whether a higher toxicity is outweighed by those advantages.
Cite
CITATION STYLE
APA
Stintzing, S., & Heinemann, V. (2016). Sym004: Truly a new level of anti-EGFR treatment? Cancer Discovery, 5(6), 578–580. https://doi.org/10.1158/2159-8290.CD-15-0441
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free